YMAB Y-Mabs Therapeutics Inc
651
$12.40
$0.45
(3.50%)
| Watchers | 651 |
| 52-Wk Low | $4.60 |
| 52-Wk High | $20.90 |
| Market Cap | $544.14M |
| Volume | 246,561.00 |
| 52-Wk High | $20.90 |
| 52-Wk Low | $4.60 |
Y-mAbs Therapeutics (YMAB, $16.19) Stochastic Oscillator left the overbought zone on April 01, 2024Tickeron - Stocks • about 2 months ago
This is a signal that YMAB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
Share to Feed
Public Employees Retirement System of Ohio trimmed its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB Free Report) by 11.0% during the third quarter, according to its most recent disclosure...
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB Get Free Report) shot up 3.9% on Tuesday . The stock traded as high as $16.33 and last traded at $16.33. 4,518 shares traded hands during...
This indicator may be signaling YMAB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
Shares of Y-mAbs Therapeutics, Inc. (YMAB) have gained 1% over the past four weeks to close the last trading session at $16.50, but there could still be a solid upside left in the stock if short-term...
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB Get Free Report) have been assigned an average recommendation of Hold from the seven research firms that are presently covering...
This price move could be a signal that YMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs ) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Trexquant Investment LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB Free Report) by 417.5% in the third quarter, according to the company in its most recent filing with the...